Covid-19 Vaccine from Beijing Appears Safe, Initial Shows Good Response

Yolanda Curtis
November 20, 2020

Oxford University will start an initial analysis of data from its late-stage trial after 53 infections among its volunteers, the study's chief investigator said on Thursday.

The Oxford-AstraZeneca COVID-19 vaccine candidate had been among the front-runners in global efforts to develop shots to protect against coronavirus infection. From the 560 volunteers, 240 of them were over the age of 70 years.

He added it was still too early to determine whether their vaccine could effectively prevent COVID-19.

Within the past two weeks, Pfizer and Moderna have both shown promising results from trials of their COVID-19 vaccines.

The comments from Professor Andrew Pollard, study lead from the University of Oxford, per the BBC, come amid news on Thursday that the vaccine induced an immune response, including in participants over age 70, per phase 2 trial data.

The manufacturers said the vaccine was undergoing larger, more comprehensive phase 3 trials to confirm the results.

No serious adverse health events related to the vaccine were seen in the participants and older people were found to have fewer side effects (such as fatigue and muscle ache) than younger participants.

Because only a Phase 3 trial includes enough people - and runs for long enough for the volunteers included to actually catch Covid - and therefore prove whether your vaccine works or not.

The Kremlin issued a statement saying Putin and Netanyahu had discussed potential cooperation regarding the Russian vaccine, including supplying it to Israel and even producing it in the Jewish state.

The researchers said that two doses of CoronaVac at different concentrations and using different dosing schedules had goof tolerance and moderately immunogenic in healthy adults aged between 18-59 years.

A vial of Russia's experimental Sputnik V coronavirus vaccine, in Moscow, Russia, September 15, 2020.

Russian Federation registered the vaccine for public use in August, in an unusual move, before the phase 3 trials were started in September. This is an important milestone as this group is considered "high risk" as they are the most vulnerable to the virus which is oftentimes fatal.

But rival drugmakers Pfizer Inc, BioNTech and Moderna Inc. have in the past 10 days edged ahead, releasing data from late-stage COVID-19 vaccine trials that shows more than 90 per cent efficacy.

In 2021, they estimate up to 1.3 billion doses.

Israel is also working on a home-grown vaccine, though it is now only in phase 1 trials and its development is expected to take months longer than the foreign candidates.

Other reports by iNewsToday